On Monday, Shares of Incyte Corporation (NASDAQ:INCY) decreased -0.98% and closed at $129.56 after opening 130.41 with the overall traded volume of 915,957 shares. The company’s Market capitalization reached to $27.29 billion, $204.77 million outstanding shares. Its low price was $127.01 and the highest price was $130.41.
On July 3, 2017 Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) granted marketing approval for Olumiant® (baricitinib) 2-mg and 4-mg tablets for the treatment of rheumatoid arthritis (RA) (including the prevention of structural injury of joints) in patients with inadequate response to standard-of-care therapies.
The Olumiant approval is based on the results of the baricitinib development program, which includes four phase 3 clinical trials enrolling various populations of more than 3,000 moderate-to-severe RA patients worldwide, including more than 500 Japanese patients. In clinical studies, baricitinib has demonstrated significant improvement in the signs and symptoms of RA compared to standard-of-care therapies.
Despite clinical advances in the treatment of RA, some people do not achieve optimal control of their disease or they discontinue treatment due to lack of efficacy or side effects, which can lead to long-term damage and disability. In Japan, an estimated 700,000-800,000 people suffer from RA, and women are three times more likely to be affected than men.
Shares of Global Blood Therapeutics Inc (NASDAQ:GBT) decreased -2.25% and closed at $28.20 after opening 28.55 with the overall traded volume of 554,492 shares. The company’s Market capitalization reached to $1.23 billion, $43.61 million outstanding shares. Its low price was $28.08 and the highest price was $29.25. The EPS is -2.50.
Global Blood Therapeutics Inc (GBT) on July 10, 2017 announced that it has expanded the ongoing HOPE-KIDS 1 Study (GBT440-007), a Phase 2a open-label study of GBT440 in pediatric patients with sickle cell disease (SCD), to include a new single-dose cohort in children age 6 to 11.
“Following positive pharmacokinetic and safety results from the single-dose cohort of adolescent patients age 12 to 17, which were recently presented at the Congress of the European Hematology Association, we have dosed the first patient in a new cohort of younger children, age 6 to 11,” said Ted W. Love, M.D., president and chief executive officer of GBT. “We believe a new treatment option for SCD is desperately needed for patients of all ages and have designed our development program to generate data across age groups. We anticipate data from this new single-dose cohort in younger pediatric participants later this year, which will help inform future GBT440 dose selections for continued evaluation in children.”